DiaMonTech

Focus: DiaMonTech is a Berlin-based biotechnology company founded in 2023 focused on non-invasive glucose monitoring devices for diabetes management. The company is early-stage with minimal disclosed scale and is currently in feasibility study phases.

Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About DiaMonTech

AI assessmentNot Hiring

No open roles listed right now. Follow DiaMonTech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry

Diabetes Mellitus Type 2

N/A

Clinical Trials (1)

NCT06088615Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry

N/A

Help build intelligence for DiaMonTech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build a company from ground zero in a high-impact metabolic disease space with unmet clinical need for non-invasive monitoring
Medical device innovation in glucose monitoring addresses a massive global diabetes market with recurring revenue potential
Early-stage Berlin biotech offers potential equity upside and hands-on role scope before institutional funding rounds

Watch Out For

Extremely limited hiring (1 active role) signals either capital constraints or very early operational stage with execution risk
No public revenue, funding data, or employee count disclosed; financial stability and runway are completely opaque
Only 2 feasibility studies in pipeline with no Phase 1/2/3 clinical progression; regulatory pathway and commercial viability remain unvalidated

Generated by Claude from DiaMonTech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Feasibility Study of Blood Glucose Monitoring With the Non-invasive Medical Device D-Base

Diabetes Mellitus, Type 1

N/A

Clinical Trials (1)

NCT05169034Feasibility Study of Blood Glucose Monitoring With the Non-invasive Medical Device D-Base

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 2 clinical trials

Top TAs: Metabolic Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Metabolic Diseases

2 pipeline

Marketed

Pipeline